4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
10-Q - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)
PITTSBURGH, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (NASDAQ:LIPO) ("Lipella") will participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York City at the Lotte New York Palace Hotel on September 9 through 11, 2024. Admission to H.C. Wainwright's conference is for qualified investors, and Lipella will be giving a virtual presentation and management will be available for one-on-one meetings onsite. For more information and/or to register for the Global Investment Conference, please visit: HCW Events H.C. Wainwright's 26th Annual Global Investment Conference: Date: September 9 through 11, 2024Location: Lotte New York Palace HotelWebc
Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouthNo FDA-approved therapy currently exists for OLPPatient registry and OLP study information is now available PITTSBURGH, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (NASDAQ:LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry. This online platform is designed to enhance research and drive the development of new treatments for OLP, a chronic inflammatory disease affecting the mucous membranes of the mouth. Characterized by symptoms such as burning pain, white patches, swollen tissue, and open sores, OLP impacts approximately 6 million Ame
LP-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancerNovel MRI contrast agent, which received support from National Institute of Diabetes and Digestive and Kidney Diseases5th International Consultation on Interstitial Cystitis Japan runs Aug. 21-23 in Kyoto PITTSBURGH, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a clinical-stage biotech company, will highlight clinical data on LP-20, a novel MRI contrast agent designed for diagnosing interstitial cystitis and detecting bladder cancer at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan, taking place August 21-23, 2024. LP-20,
SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)
Shares of ASP Isotopes Inc. (NASDAQ:ASPI) fell during Friday's session after the company announced pricing of a $30 million public offering of 12 million shares at $2.50 per share. ASP Isotopes shares fell 9.2% to $3.2308 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Vicinity Motor Corp. (NASDAQ:VEV) shares jumped 133.2% to $0.7910 after the company announced CARB certification for the VMC 1200 class 3 electric truck. Qualigen Therapeutics, Inc. (NASDAQ:QLGN) shares rose 110% to $0.4335. TOYO Co., Ltd (NASDAQ:TOYO) climbed 63.4% to $2.5322. Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN) jumped 58% to $9.52 foll
Shares of Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) rose sharply in today's pre-market trading after the company reported better-than-expected second-quarter sales and issued guidance. Ericsson reported a second-quarter loss of 31 cents per share, compared to year-ago earnings of 7 cents per share. The company reported quarterly sales of $5.59 billion which beat the analyst consensus estimate of $5.36 billion, according to data from Benzinga Pro. Ericsson shares jumped 4.3% to $6.66 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Sentage Holdings Inc. (NASDAQ:SNTG) rose 85.6% to $4.27 in pre-market trading after gaining around 5% on